Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)
This study has been completed.
Information provided by:
First received: February 24, 2009
Last updated: March 25, 2011
Last verified: March 2011
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||March 2011|
|Primary Completion Date:||August 2006 (Final data collection date for primary outcome measure)|
Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, Bett AJ, Casimiro DR, Shiver JW, Dinubile MJ, Quirk E; for the Merck V526-001 Study Group. Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults. Clin Vaccine Immunol. 2009 Sep;16(9):1285-1292. Epub 2009 Jul 15.